000130507 001__ 130507 000130507 005__ 20240125162931.0 000130507 0247_ $$2doi$$a10.1002/cncr.24141 000130507 0248_ $$2sideral$$a129739 000130507 037__ $$aART-2009-129739 000130507 041__ $$aeng 000130507 100__ $$0(orcid)0000-0003-2078-8205$$aGarcia, Mar 000130507 245__ $$aProliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine 000130507 260__ $$c2009 000130507 5203_ $$aBACKGROUND: It has been demonstrated that the tumor proliferation index has prognostic significance in patients with mantle cell lymphoma (MCL). Patients in most of studies, however, have been treated with relatively traditional chemotherapy regimens. At the authors' institution, patients with MCL received an aggressive chemotherapy regimen: rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine (R-hyper-CVAD). METHODS: The authors assessed the proliferation rate of MCL using immunohistochemistry and an antibody specific for Ki-67 in 71 untreated patients who subsequently received R-hyper-CVAD. The study group included 59 patients who had classic MCL and 12 patients who had the blastoid variant of MCL. RESULTS: For the entire study group and for the group of patients with classic MCL, a proliferation index of >20% Ki-67-positive cells was correlated significantly with shorter failure-free survival. There was no correlation between the proliferation index and overall survival. CONCLUSIONS: The current results indicated that the proliferation index in patients with MCL predicted prognosis in those who uniformly received the R-hyper-CVAD chemotherapy regimen. 000130507 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/ 000130507 590__ $$a5.418$$b2009 000130507 591__ $$aONCOLOGY$$b21 / 164 = 0.128$$c2009$$dQ1$$eT1 000130507 655_4 $$ainfo:eu-repo/semantics/article 000130507 700__ $$aRomaguera, Jorge E. 000130507 700__ $$aInamdar, Kedar V. 000130507 700__ $$aRassidakis, George Z. 000130507 700__ $$aMedeiros, L. Jeffrey 000130507 773__ $$g115, 5 (2009), 1041-1048$$pCancer$$tCANCER$$x0008-543X 000130507 8564_ $$s388534$$uhttps://zaguan.unizar.es/record/130507/files/texto_completo.pdf 000130507 8564_ $$s1662737$$uhttps://zaguan.unizar.es/record/130507/files/texto_completo.jpg?subformat=icon$$xicon 000130507 909CO $$ooai:zaguan.unizar.es:130507$$particulos$$pdriver 000130507 951__ $$a2024-01-25-15:16:23 000130507 980__ $$aARTICLE